FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
JW (Cayman) Therapeutics Co. Ltd Stock AnalysisComprehensive stock analysis for JW (Cayman) Therapeutics Co. Ltd (JWCTF) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisJWCTF
JWCTF
JW (Cayman) Therapeutics Co. Ltd
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
JWCTF
Home🔹Stocks🔹JW (Cayman) Therapeutics Co. Ltd

JW (Cayman) Therapeutics Co. Ltd

JWCTF•OTC

JW (Cayman) Therapeutics Co. Ltd

JWCTF•OTC
Market cap
$127.50M
Sentiment

Your view on JWCTF

Mkt Cap
$127.50M
Sentiment
Your view
JWCTF
JW (Cayman) Therapeutics Co. Ltd
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
JWCTF
Company Overview

Overview

What the company does, where it operates, and who runs it.

About JW (Cayman) Therapeutics Co. Ltd

Industry
Biotechnology
Sector
Healthcare
CEO
Min Liu
Headquarters
Building B, Shanghai, CN
Industry
Biotechnology
Sector
Healthcare
CEO
Min Liu
Headquarters
Building B, Shanghai, CN
Description

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers. The company's pipeline products include JWCAR129, an autologous CAR-T therapy for the treatment of multiple myeloma; JWATM204, a TCR T-cell therapy candidate for the treatment of HCC; and JWATM203, an autologous T-cell receptor mimic T-cell therapy targeting alpha-fetoprotein for the treatment of hepatocellular carcinoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News